
|Articles|December 1, 2004
Miravant selects new name for SnET2
Santa Barbara, CA-Miravant Medical Technologies has picked Photrex as the brand name for its tin ethyl etiopurpurin (SnET2) drug being developed for photodynamic therapy in the treatment of wet AMD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Metformin use associated with reduced incidence of intermediate AMD
2
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
3
Last year in glaucoma at EnVision Summit 2025
4
Looking back at the 2025 EnVision Summit
5




























